S100A8 and systemic sclerosis: adopted the SELDI-TOF-MS examination of plasma from SSc patients with and without ILD and showed that S100A8 (calprotectin) levels were significantly increased in patients with SSc-ILD (21), which was consistent with the findings by Fietta et al.